AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

10,062.00p
   
  • Change Today:
      93.00p
  • 52 Week High: 13,276.00p
  • 52 Week Low: 9,501.00p
  • Currency: UK Pounds
  • Shares Issued: 1,550.30m
  • Volume: 4,889,045
  • Market Cap: £155,992m
  • RiskGrade: 123
  • Beta: 0.87

AstraZeneca says does not comment on media reports as shares slump

By Michele Maatouk

Date: Tuesday 05 Nov 2024

LONDON (ShareCast) - (Sharecast News) - AstraZeneca said on Tuesday that it does not comment on speculative media reports, in response to a sharp drop in its share price.

"As a matter of policy, we do not comment on speculative media reports including those related to ongoing investigations in China," the pharmaceuticals firm said in a brief statement just after the close of London markets.

"If requested, we will fully cooperate with the Chinese authorities," it said. "We continue to deliver our life changing medicines to patients in China and our operations are ongoing."

The statement came after the shares closed down 8.4% following a Yicai report that dozens of senior executives at the company in China have been implicated in an ongoing insurance fraud case as of last week.

Yicai cited a person familiar with the matter as saying that Leon Wang, president of AstraZeneca China, is cooperating with the investigation by Chinese authorities, which has now expanded to include the public security bureau, supervisory commission, and other relevant bodies.

The key figure who should have cooperated with the inquiry was another senior executive at AstraZeneca China, the source added.

Yicai noted that over the past three years, insurance fraud cases involving AstraZeneca have surfaced in Shenzhen as well as the provinces of Fujian and Jiangxi. Employees implicated in these have pointed the finger at regional managers, district managers, and even senior executives.

These cases amount to the largest insurance fraud in the nation's pharmaceutical sector for years, a person familiar with the matter said. So far, dozens of AstraZeneca staff have been convicted of fraud, with the main offenders receiving prison sentences of over 10 years.

Yicai said an insider at a drugmaker noted that AstraZeneca's high sales targets put extreme pressure on medical reps, which has been a major factor in the firm's compliance issues.

AstraZeneca announced at the end of last month that Wang was under investigation and cooperating with Chinese authorities.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 10,062.00p
Change Today 93.00p
% Change 0.93 %
52 Week High 13,276.00p
52 Week Low 9,501.00p
Volume 4,889,045
Shares Issued 1,550.30m
Market Cap £155,992m
Beta 0.87
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
87.66% below the market average87.66% below the market average87.66% below the market average87.66% below the market average87.66% below the market average
88% below the sector average88% below the sector average88% below the sector average88% below the sector average88% below the sector average
Price Trend
27.11% below the market average27.11% below the market average27.11% below the market average27.11% below the market average27.11% below the market average
34.69% above the sector average34.69% above the sector average34.69% above the sector average34.69% above the sector average34.69% above the sector average
Income
78.05% below the market average78.05% below the market average78.05% below the market average78.05% below the market average78.05% below the market average
42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average
Growth
88.44% above the market average88.44% above the market average88.44% above the market average88.44% above the market average88.44% above the market average
94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average94.12% above the sector average

What The Brokers Say

Strong Buy 9
Buy 15
Neutral 5
Sell 0
Strong Sell 1
Total 30
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  1st Interim 2nd Interim
Ex-Div 08-Aug-24 22-Feb-24
Paid 09-Sep-24 25-Mar-24
Amount 100.00¢ 197.00¢

Trades for 21-Nov-2024

Time Volume / Share Price
14:33 580,525 @ 9,867.00p
16:23 506,887 @ 9,866.30p
14:33 580,525 @ 9,867.00p
16:23 506,887 @ 9,867.00p
16:03 0 @ 10,030.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page